Welcome to the Innate Immunotherapy Summit 2020
Recognizing the importance of the relatively untapped innate immune system as a possible tool for therapeutic intervention, the 2nd Annual Innate Immunotherapy Summit will convene all thought leaders including industry experts,
academic researchers and clinicians to deepen our understanding of innate immunity and learn to harness its power for effective immunotherapies. This two-day congress focuses on the current landscape and novel advances in the field
of innate immunotherapy, such as natural killer cells, macrophages and dendritic cells. Be part of the conversation on mechanisms of action of innate cells, effective modulating strategies, the impact of tumor microenvironment
and many more. Share new insights and learn from others to maximize the success of your strategies in an intimate setting created for participants to exchange innovative ideas, foster meaningful collaborations and keep up-to-date
with new discoveries in the innate immunity research community.
Michael V. Callahan MD, DTM&H, MSPH
President & Chief Medical Officer, United Therapeutics Corporation
Michael Klichinsky, PharmD, PhD
Co-Founder, Vice President, Carisma Therapeutics
Hans Klingemann, MD, PhD
Vice President, NantKwest, Inc.
Mark Lowdell, PhD
Director, Centre for Cell, Gene & Tissue Therapeutics, RFH; Professor, University College London
Shiladitya Sengupta, PhD
Principle Investigator, Harvard Medical School and Massachusetts Institute of Technology
RJ Tesi, MD
CEO, CMO, INmune Bio